Nadmed

NADMED, a Finnish startup, operates in the biotechnology sector, providing innovative solutions for the measurement of NADs (Nicotinamide adenine dinucleotide), a crucial metabolite in the human body. The company's primary offerings include Q-NADMED blood and Q-NAD kits, which are designed to measure NADs from any sample type. These products cater to research institutions and drug development companies, aiding in their scientific studies and product development processes.

NADMED's business model revolves around the sale of these kits and the provision of laboratory services to support research and drug development. The company's unique selling proposition lies in its proprietary technology, developed in collaboration with the University of Helsinki, which allows for accurate colorimetric quantification of NADs and two glutathiones, even from a minuscule amount of blood. This technology is capable of measuring metabolites individually, a feature not available in other existing methods.

The company's revenue generation is primarily through the sale of these kits and the provision of laboratory services. The demand for such a quick, reliable, and cost-effective method of measuring NADs has been on the rise, given the increasing links found between NAD levels and various diseases. This demand, coupled with the lack of a reliable method, has driven the development and success of NADMED's technology.

Keywords: Biotechnology, NADs Measurement, Research Support, Drug Development, Laboratory Services, Colorimetric Quantification, Metabolites Measurement, University of Helsinki, Reliable Testing, Disease Research.